Adipearl™ injectable dermal filler

	Next higher product group	biomaterials_o
	Status	2024-03-25 development pc existent
	Organisation	Volumina Medical S.A.

Volumina Medical SA. (3/25/24). "Press Release: Volumina Medical Secures USD 21 Million Funding to Continue Its Clinical Program after Having Obtained Promising First in Human Data". Epalinges.

Volumina Medical, a clinical stage MedTech company developing novel biomaterials for dermatology and plastic surgery, announces the successful closing of their Series A round by existing and new investors. It will enable Volumina Medical to confidently advance its clinical program with its lead product Adipearl™, and ultimately achieve market approval in key international markets.

Adipearl™ product is an innovative injectable dermal filler enabling the regeneration of soft tissues. This breakthrough innovation addresses a high unmet need of millions of patients that require the reconstruction or regeneration of tissues after surgery, disease or for aesthetic purposes. The product is currently being used in clinical trials by world-renowned KOLs in Europe.

The funding will be used to gather additional and valuable clinical data to bring Adipearl™ to the market and ultimately help millions of patients that currently lack natural and durable solutions for improving their health and wellbeing.

“I will never forget the intensity of the smiles on face of the first patients that were treated with Adipearl™. Together with this funding round it is providing us a lot of confidence and an extremely high energy to continue to develop Volumina Medical and offer our solution to millions of patients”, said Amélie Béduer, CEO and CO-Founder of Volumina.

“Adipearl™ is receiving a lot of traction from the market and the results are very promising. This new funding round provides a strong commitment and allows the Volumina team to continue its steady progress and answer a true need of patients”, commented Silvia Scherer, Chairwoman of the board.

About Volumina Medical

Volumina Medical was incorporated in Switzerland in 2018 as a spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL) with the vision of improving patients’ lives by providing game changing products to the aesthetic dermatology and plastic and reconstructive surgery markets through the development of biomaterials that enable the body to regenerate its own tissues. For more information, please visit our website: www.volumina-medical.ch

Initially financed by BlueOcean Ventures, ZKB, Skyviews Lifesciences, Clinique La Prairie and private investors, Volumina Medical has been supported by various programs and institutions, including Innosuisse, Venture Kick, Venturelab, the Gebert Rüf Foundation, de Vigier Foundation, the Service de la promotion de l’économie et de l’innovation (SPEI), the Vanguard Accelerator at Biopôle. The prix PERL, Prix Strategis, and the European Institute of Innovation and Technology (EIT Health).

Record changed: 2024-04-04

Picture biomindz Mainz Biomed LSG Colorectal Cancer Screening 650x200px

More documents for biomaterials

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)